Summary
Vertex Pharmaceuticals Inc. (VRTX) filed an 8-K report on April 29, 2013, to announce its financial results for the first quarter ended March 31, 2013. The primary purpose of this filing is to incorporate by reference a press release issued by the company on April 30, 2013, which contains detailed financial and operational information for the reported period. Investors should refer to the attached press release for specific metrics regarding revenue, earnings, and any significant business updates that may have occurred during the quarter.
Key Highlights
- 1Vertex Pharmaceuticals (VRTX) announced its Q1 2013 financial results via press release on April 30, 2013.
- 2The 8-K filing serves to formally include the Q1 2013 earnings press release as an exhibit.
- 3Investors are directed to the press release (Exhibit 99.1) for the specific details of the financial results and operational performance for the quarter ended March 31, 2013.
- 4The press release contains consolidated financial results for the period.
- 5Information furnished in the press release is not considered 'filed' under Section 18 of the Exchange Act, meaning it doesn't carry the same liability as formally filed information, but is still material for investors.